NCT05740280View on ClinicalTrials.gov

iCP-NI - Safety, Tolerability, Pharmacokinetic, and Immunogenicity Study in Healthy Male and Female Subjects

PHASE1TerminatedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 19, 2023

Primary Completion Date

April 20, 2023

Study Completion Date

April 20, 2023

Conditions
Healthy Volunteers
Interventions
DRUG

iCP-NI

20 mg/mL iCP-NI solution for intravenous injection

DRUG

Placebo

Placebo solution for intravenous injection

Trial Locations (1)

32117

Labcorp Clinical Research Unit Inc., Daytona Beach

Sponsors
All Listed Sponsors
collaborator

Labcorp Corporation of America Holdings, Inc

INDUSTRY

lead

Cellivery Therapeutics, Inc.

INDUSTRY